RARA CRAFT DATABASE for FDA Medical Devices
510(k)K250342

FDA DEVICE FACTS

Powder-Free Polychloroprene Examination Glove (Green Color) Tested for Use with Chemotherapy Drugs and Fentanyl

Encompass Industries Sdn. Bhd.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEJuly 8, 2025PRODUCT CODELZA

Indications for use

A powder-free patient examination glove is a disposable device intended for medical purposes that is worn on examiner's hand to prevent contamination between patient and examiner. In addition, the glove was evaluated using ASTM D6978 for permeation of chem otherapy drugs and fentanyl citrate. The glove is single use and non-sterile.

The following chemotherapy drugs have been tested on the glove:

Chemotherapy Drug Concentration Minimum Breakthrough Detection Time (minutes) Carmustine (BCNU)* 3.3 mg/ml 23.2 min Cisplatin 1.0 mg/ml >240 min Cyclophosphamide 20.0 mg/ml >240 min Dacarbazine 10.0 mg/ml >240 min Doxorubicin HCL 2.0 mg/ml >240 min Etoposide 20.0 mg/ml >240 min Fluorouracil 50.0 mg/ml >240 min Methotrexate 25.0 mg/ml >240 min Paclitaxel 6.0 mg/ml >240 min ThioTepa* 10.0 mg/ml 13.5 min Mitomycin C 0.5 mg/ml >240 min Vincristine Sulfate 1.0 mg/ml >240 min *Warning Statement: Please note that the following drugs have extremely low permeation time:

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: September 1, 2026